Thiogenesis Therapeutics Corp
Toronto Stock Exchange VenturesTotal Valuation
Thiogenesis Therapeutics Corp carries a market capitalization of 34.29M, placing it among publicly traded companies globally.
| Market Cap | 34.29M |
| Enterprise Value | N/A |
Share Statistics
Thiogenesis Therapeutics Corp currently has 69.98M shares outstanding.
| Shares Outstanding | 69.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 5.62 |
| P/TBV Ratio | 5.62 |
| P/FCF Ratio | -4.27 |
| P/OCF Ratio | -4.27 |
Financial Position
Thiogenesis Therapeutics Corp maintains a current ratio of 10.81, meaning it holds 10.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.81 |
| Quick Ratio | 10.69 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -181.53 |
| Return on Assets (ROA) | -139.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Thiogenesis Therapeutics Corp's stock has declined approximately -30% over the past 52 weeks. The 50-day moving average sits at 0.53, while the 200-day moving average is 0.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.55 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -6.52M, while operating income came in at -6.52M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -6.52M |
| Pretax Income | -6.52M |
| Net Income | -6.52M |
| EBITDA | -6.52M |
| EBIT | -6.52M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
Total book value stands at 6.72M, with working capital of 6.72M providing operational flexibility.
| Cash & Cash Equivalents | 7.27M |
| Total Debt | N/A |
| Net Debt | -7.27M |
| Equity (Book Value) | 6.72M |
| Book Value Per Share | 0.10 |
| Working Capital | 6.72M |
Cash Flow
Thiogenesis Therapeutics Corp produced -6.73M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.73M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.73M |
| FCF Per Share | -0.13 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.09 |
| FCF Yield | -23.40 |
Scores
Thiogenesis Therapeutics Corp posts an Altman Z-Score of 26.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 26.70 |